Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Immuneering Corp (IMRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: IMRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 52.08% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 58.86M USD | Price to earnings Ratio - | 1Y Target Price 11.7 |
Price to earnings Ratio - | 1Y Target Price 11.7 | ||
Volume (30-day avg) 201077 | Beta -0.33 | 52 Weeks Range 1.00 - 3.83 | Updated Date 04/1/2025 |
52 Weeks Range 1.00 - 3.83 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.04 |
Earnings Date
Report Date 2025-03-21 | When - | Estimate -0.445 | Actual -0.58 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51.57% | Return on Equity (TTM) -92.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22566760 | Price to Sales(TTM) 563.62 |
Enterprise Value 22566760 | Price to Sales(TTM) 563.62 | ||
Enterprise Value to Revenue 191913.54 | Enterprise Value to EBITDA -1.53 | Shares Outstanding 35887300 | Shares Floating 27234477 |
Shares Outstanding 35887300 | Shares Floating 27234477 | ||
Percent Insiders 24.07 | Percent Institutions 12.11 |
Analyst Ratings
Rating 3.86 | Target Price 12.42 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Immuneering Corp
Company Overview
History and Background
Immuneering Corp. is a biopharmaceutical company focused on developing novel therapeutics for oncology and other diseases. Founded in 2008, it leverages computational biology to identify new drug targets and develop personalized medicines. They went public in January 2022.
Core Business Areas
- Drug Development: Developing novel therapies targeting unmet needs in oncology and other disease areas by leveraging Disease Cancelling Technology.
- Computational Biology Platform: Utilizing a proprietary computational biology platform to identify and validate drug targets.
Leadership and Structure
The leadership team consists of Geoffrey F. Wile, Ph.D. (Co-Founder and Chief Scientific Officer), Ben Zeskind (Co-Founder and Chief Executive Officer), and other executives overseeing key departments. The structure is typical of a publicly traded biopharmaceutical company.
Top Products and Market Share
Key Offerings
- IMM-1-104: A MEK inhibitor prodrug being developed for advanced solid tumors with RAS mutations. It is currently in Phase 1/2a clinical trials. Market share data is not yet available, as it is still in clinical development. Competitors include companies developing MEK inhibitors, such as Trametinib (Novaris) and Cobimetinib (Genentech).
- IMM-6-415: A novel dual-mechanism candidate to address RAS-mediated resistance, with the potential to be a combination partner in RAS-driven tumors, or for diseases characterized by hyperactive RAS signalling. Market share data is not yet available, as it is still in clinical development. Competitors include companies targeting RAS pathways, such as Mirati Therapeutics and Amgen.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and stringent regulatory requirements. The oncology market is a significant driver of growth, with increasing demand for novel therapies.
Positioning
Immuneering Corp. is positioned as a computationally driven drug discovery company focused on developing personalized medicines. Their competitive advantage lies in their proprietary computational biology platform and their focus on challenging drug targets.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Immuneering Corp. is positioned to capture a portion of this market through its development of novel therapies for specific cancer subtypes. The exact TAM for their specific targets is dependent on clinical trial results and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary computational biology platform
- Experienced management team
- Focus on challenging drug targets
- Strong intellectual property portfolio
Weaknesses
- Limited number of clinical-stage assets
- High reliance on research and development funding
- Potential for clinical trial failures
- Reliance on third-party manufacturers.
Opportunities
- Expansion of pipeline through internal development and strategic collaborations
- Potential for breakthrough therapies in oncology
- Increasing demand for personalized medicines
- Partnerships with major pharmaceutical companies.
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Clinical trial failures
- Changes in reimbursement policies
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- NVS
- MRTX
- AMGN
- LLY
Competitive Landscape
Immuneering's advantage lies in its computational biology platform for drug discovery. Disadvantages include limited financial resources compared to larger pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expanding its research and development activities and progressing its drug candidates through preclinical and clinical stages.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its drug candidates. Analyst estimates vary widely depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing IMM-1-104 and IMM-6-415 through clinical trials, expanding their computational biology platform, and forming strategic collaborations.
Summary
Immuneering Corp. is a computationally driven biopharmaceutical company focused on developing novel therapies. Its strength lies in its proprietary platform and experienced team, but it faces challenges related to clinical trial risks and competition from larger firms. Successful clinical trials and strategic partnerships are crucial for its future growth. Investing is high risk as they are relying on R&D.
Similar Companies
- MRTX
- AMGN
- LLY
- NVS
Sources and Disclaimers
Data Sources:
- Immuneering Corp. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in biopharmaceutical companies involves significant risk, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immuneering Corp
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-07-30 | Co-Founder, President, CEO & Director Dr. Benjamin J. Zeskind M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 66 | Website https://immuneering.com |
Full time employees 66 | Website https://immuneering.com | ||
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.